This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 95/10/998    most recent 01.RES.0000147558.15554.67v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lee, R. G. Articles by Rudel, L. L. Search for Related Content PubMed PubMed Citation Articles by Lee, R. G. Articles by Rudel, L. L. Related Collections Lipid and lipoprotein metabolism Pathophysiology Risk Factors Genetically altered mice

(Circulation Research. 2004;95:998.)
© 2004 American Heart Association, Inc.

Molecular Medicine

Plasma Cholesteryl Esters Provided by Lecithin:Cholesterol Acyltransferase and Acyl-Coenzyme A:Cholesterol Acyltransferase 2 Have Opposite Atherosclerotic Potential

Richard G. Lee, Kathryn L. Kelley, Janet K. Sawyer, Robert V. Farese, Jr, John S. Parks, Lawrence L. Rudel

From the Arteriosclerosis Research Program (R.G.L., K.L.K., J.K.S., J.S.P., L.L.R.), Departments of Pathology and Biochemistry, Wake Forest University School of Medicine Winston-Salem, NC; Gladstone Institute of Cardiovascular Disease (R.V.F.), San Francisco, Calif.

Correspondence to Lawrence L. Rudel, PhD, Department of Pathology, Wake Forest University School of Medicine, Medical Center Blvd, Winston-Salem, NC 27157. E-mail lrudel{at}wfubmc.edu

Evidence suggests that ACAT2 is a proatherogenic enzyme that contributes cholesteryl esters (CEs) to apoB-containing lipoproteins, whereas LCAT is an antiatherogenic enzyme that facilitates reverse cholesterol transport by esterifying free cholesterol on HDL particles. We hypothesized that deletion of LCAT and ACAT2 would lead to absence of plasma CEs and reduced atherosclerosis. To test this hypothesis, ACAT2^–/– LCAT^–/– LDLr^–/–, ACAT2^–/– LDLr^–/–, and LCAT^–/– LDLr^–/– mice were fed a 0.15% cholesterol diet for 20 weeks. In comparison to LDLr^–/– mice, the total plasma cholesterol (TPC) of ACAT2^–/– LCAT^–/– LDLr^–/– mice was 67% lower because of the complete absence of plasma CEs, leading to 94% less CE accumulation in the aorta. In the LCAT^–/– LDLr^–/– mice, TPC and atherosclerosis were significantly higher because of increased accumulations of ACAT2-derived CE. In ACAT2^–/– LDLr^–/– mice, again compared with LDLr^–/– mice, TPC was 19% lower, whereas atherosclerosis was 88% lower. Therefore, the absence of ACAT2 led to a significant reduction in TPC although benefits in reduction of atherosclerosis were much more pronounced. Overall, the data suggest that ACAT2-derived CE is the predominant atherogenic lipid in blood, and that an important goal for prevention of atherosclerosis is to limit ACAT2-derived CE accumulation in lipoproteins.

Key Words: LCAT • ACAT2 • atherosclerosis • cholesterol • cholesteryl esters • lipoproteins

This article has been cited by other articles:

				A. Das, M. A. Davis, and L. L. Rudel Identification of putative active site residues of ACAT enzymes J. Lipid Res., August 1, 2008; 49(8): 1770 - 1781. [Abstract] [Full Text] [PDF]

				P. Parini, U. Gustafsson, M. A. Davis, L. Larsson, C. Einarsson, M. Wilson, M. Rudling, H. Tomoda, S. Omura, S. Sahlin, et al. Cholesterol Synthesis Inhibition Elicits an Integrated Molecular Response in Human Livers Including Decreased ACAT2 Arterioscler. Thromb. Vasc. Biol., June 1, 2008; 28(6): 1200 - 1206. [Abstract] [Full Text] [PDF]

				J. M. Brown, T. A. Bell III, H. M. Alger, J. K. Sawyer, T. L. Smith, K. Kelley, R. Shah, M. D. Wilson, M. A. Davis, R. G. Lee, et al. Targeted Depletion of Hepatic ACAT2-driven Cholesterol Esterification Reveals a Non-biliary Route for Fecal Neutral Sterol Loss J. Biol. Chem., April 18, 2008; 283(16): 10522 - 10534. [Abstract] [Full Text] [PDF]

				A. Das, M. A. Davis, H. Tomoda, S. Omura, and L. L. Rudel Identification of the Interaction Site within Acyl-CoA:Cholesterol Acyltransferase 2 for the Isoform-specific Inhibitor Pyripyropene A J. Biol. Chem., April 18, 2008; 283(16): 10453 - 10460. [Abstract] [Full Text] [PDF]

				R. E. Temel, L. Hou, L. L. Rudel, and G. S. Shelness ACAT2 stimulates cholesteryl ester secretion in apoB-containing lipoproteins J. Lipid Res., July 1, 2007; 48(7): 1618 - 1627. [Abstract] [Full Text] [PDF]

				T. A. Bell III, K. Kelley, M. D. Wilson, J. K. Sawyer, and L. L. Rudel Dietary Fat-Induced Alterations in Atherosclerosis Are Abolished by ACAT2-Deficiency in ApoB100 Only, LDLr-/- Mice Arterioscler. Thromb. Vasc. Biol., June 1, 2007; 27(6): 1396 - 1402. [Abstract] [Full Text] [PDF]

				T. A. Bell III, M. D. Wilson, K. Kelley, J. K. Sawyer, and L. L. Rudel Monounsaturated fatty acyl-coenzyme A is predictive of atherosclerosis in human apoB-100 transgenic, LDLr-/- mice J. Lipid Res., May 1, 2007; 48(5): 1122 - 1131. [Abstract] [Full Text] [PDF]

				R. V. Farese Jr The nine lives of ACAT inhibitors. Arterioscler. Thromb. Vasc. Biol., August 1, 2006; 26(8): 1684 - 1686. [Full Text] [PDF]

				T. A. Bell III, J. M. Brown, M. J. Graham, K. M. Lemonidis, R. M. Crooke, and L. L. Rudel Liver-Specific Inhibition of Acyl-Coenzyme A:Cholesterol Acyltransferase 2 With Antisense Oligonucleotides Limits Atherosclerosis Development in Apolipoprotein B100-Only Low-Density Lipoprotein Receptor-/- Mice Arterioscler. Thromb. Vasc. Biol., August 1, 2006; 26(8): 1814 - 1820. [Abstract] [Full Text] [PDF]

				L. L. Rudel, R. V. Farese Jr., and S. E. Nissen ACAT inhibition and the progression of coronary atherosclerosis. N. Engl. J. Med., June 15, 2006; 354(24): 2616 - 2617. [Full Text] [PDF]

				R. E. Temel, R. G. Lee, K. L. Kelley, M. A. Davis, R. Shah, J. K. Sawyer, M. D. Wilson, and L. L. Rudel Intestinal cholesterol absorption is substantially reduced in mice deficient in both ABCA1 and ACAT2 J. Lipid Res., November 1, 2005; 46(11): 2423 - 2431. [Abstract] [Full Text] [PDF]

				C. Pramfalk, M. A. Davis, M. Eriksson, L. L. Rudel, and P. Parini Control of ACAT2 liver expression by HNF1 J. Lipid Res., September 1, 2005; 46(9): 1868 - 1876. [Abstract] [Full Text] [PDF]

				R. G. Lee, R. Shah, J. K. Sawyer, R. L. Hamilton, J. S. Parks, and L. L. Rudel ACAT2 contributes cholesteryl esters to newly secreted VLDL, whereas LCAT adds cholesteryl ester to LDL in mice J. Lipid Res., June 1, 2005; 46(6): 1205 - 1212. [Abstract] [Full Text] [PDF]

				L. L. Rudel, R. G. Lee, and P. Parini ACAT2 Is a Target for Treatment of Coronary Heart Disease Associated With Hypercholesterolemia Arterioscler. Thromb. Vasc. Biol., June 1, 2005; 25(6): 1112 - 1118. [Abstract] [Full Text] [PDF]